An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction

Trial Profile

An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 27 Nov 2017 Results of pooled data from two trials (NCT01273493 and NCT01343277) assessing pharmacokinetics and safety of trabectedin in patients with pre-existing hepatic impairment, were published in the Investigational New Drugs.
    • 07 Jun 2016 Results related to liver toxicity of Trabectedin from OVC1004 and SAR3007 studies presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
    • 19 May 2016 According to PharmaMar media release, results will be presented at the 52nd Congress of the American Society of Clinical Oncology (ASCO).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top